(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 49.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.2%.
X4 Pharmaceuticals's revenue in 2025 is $31,364,000.On average, 4 Wall Street analysts forecast XFOR's revenue for 2025 to be $203,674,917, with the lowest XFOR revenue forecast at $196,525,890, and the highest XFOR revenue forecast at $211,287,039. On average, 5 Wall Street analysts forecast XFOR's revenue for 2026 to be $137,516,025, with the lowest XFOR revenue forecast at $59,623,466, and the highest XFOR revenue forecast at $197,973,061.
In 2027, XFOR is forecast to generate $736,303,493 in revenue, with the lowest revenue forecast at $206,482,430 and the highest revenue forecast at $1,833,276,856.